Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration
- 1 August 2016
- journal article
- research article
- Published by Elsevier in Ophthalmology
- Vol. 123 (8) , 1731-1736
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALSRetina, 2015
- Optical Coherence Tomography, Fluorescein Angiography, and the Management of Neovascular Age-Related Macular DegenerationOphthalmology, 2015
- Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend ProtocolOphthalmology, 2015
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationBritish Journal of Ophthalmology, 2014
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisThe Lancet Global Health, 2014
- CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICERetina, 2013
- Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in GermanyActa Ophthalmologica, 2012
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular DegenerationOphthalmology, 2012
- HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011